Skip to main content

IP Update: Feb 26, 2009

Premium

Title: Pharmaceutical Composition for Obstructive Vascular Disease

Number: 20090047319

Filed: May 24, 2006 PCT Filed: May 24, 2006

Lead Inventor: Kenji Kadomatsu, Nagoya University

The patent application claims "a pharmaceutical composition for a obstructive vascular disease comprising a nucleic acid construct capable of inhibiting the expression of a midkine gene through RNA interference and a collagen molecule," according to its abstract. "The use of the nucleic acid construct capable of inhibiting the expression of an MK protein through RNA interference in the presence of the collagen molecule can provide an excellent inhibitory effect on the thickened vascular intima."


Title: Method to Treat Flavivirus Infection with siRNA

Number: 20090047338

Filed: Oct. 5, 2006 PCT Filed: Oct. 5, 2006

Lead Inventor: Manjunath Swamy, Immune Disease Institute (Harvard University)

The invention," the patent application's abstract states, "is directed to methods of treating flavivirus mediated diseases using siRNAs. The invention is based upon our findings in a mouse model that siRNAs directed against sequences conserved among multiple flaviviruses prevents and treats flavivirus infections," it adds. "Accordingly, the … invention provides an isolated siRNA comprising a sense RNA and an antisense RNA strand or a single strand. The sense and the antisense RNA strands, or the single RNA strand, form an RNA duplex, and wherein the RNA strand comprises a nucleotide sequence identical to a target sequence of about 15 to about 30 contiguous nucleotides in flavivirus mRNA or mutant or variant thereof."


Title: RNA Interference Using a Universal Target

Number: 20090048111

Filed: Sept. 5, 2008

Lead Inventor: Liwen Huang, Myriad Genetic

The invention "provides novel methods for manipulating levels of expression of gene products using RNA interference," the patent application's abstract states. "The methods disclosed can be used to investigate gene function, to create disease-resistant organisms, and to treat disease."


Title: Double-Stranded Composition Comprising Differentially Modified Strands for Use in Gene Modulation

Number: 20090048192

Filed: June 2, 2005 PCT Filed: June 2, 2005

Lead Inventor: Balkrishen Bhat, Isis Pharmaceuticals

The invention comprises "double-stranded compositions wherein each strand is modified to have a motif defined by positioning of beta-D-ribonucleosides and sugar modified nucleosides," according to the patent application's abstract. "More particularly, the … compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified motif, or a positionally modified motif. At least one of the strands has complementarity to a nucleic acid target.

"The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes," the abstract notes. "In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The … invention also provides methods for modulating gene expression."


Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules

Number:
20090048197

Filed:
Feb. 7, 2008

Lead Inventor:
Tongqian Chen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules. The invention also features compositions and methods of use for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity in a subject or organism.

"Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles, and transfection agents that effectively transfect or deliver biologically active molecules, such as … antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, dsRNA …, and small nucleic acid molecules … to relevant cells and/or tissues, such as in a subject or organism," the abstract adds. "Such novel cationic lipids, microparticles, nanoparticles, and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject, or organism. The compositions described herein are generally referred to as formulated molecular compositions or lipid nanoparticles."


Title: Compositions and Methods for Nucleic Acid Delivery Systems

Number:
20090048198

Filed:
March 3, 2008

Lead Inventor: Rumiana Koynova-Tenchova, Northwestern University

The invention "relates to compositions and methods for use in delivering nucleic acids and other agents into cells and tissues," the patent application's abstract states. "In particular, the … invention provides lipid mixtures at the gel-liquid crystalline phase transition providing superior lipofection activity for transferring materials into cells and tissues."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.